Curcumin-Galactomannoside Interaction Enhances the Bioavailability of Curcumin and Inhibits Inflammation and Oxidative Stress Associated with Experimental Arthritis

Curcumagalactomannosides (CGM) is a novel bio-available formulation. This formulation was made from curcumin (CM) and it comprises with fenugreek derived dietary fibre composed of galactose and mannose units. In the current study was designed to evaluate the anti-inflammatory action of CGM was compared with CM on carrageenaninduced acute model. The result indicated that the CGM showed the minimal dose with potent inhibitory effect than CM. CGM at 100 mg/kg bwt was found to be potent dose from carrageenan model. From the above data, we evaluated its anti-arthritic effect in adjuvant induced chronic arthritic model. Adult male wistar rats were divided into 4 groups: Normal control rats (NC); Adjuvant induced arthritic control rats (AA); AA+ CGM supplemented (100mg/kg bwt); AA+ indomethacin administrated (IND 3 mg/kg bwt) for 30 days. The activities of inflammatory markers, antioxidant enzymes, histopathology and radiology of rat paw tissue were analyzed. The result indicated that there was a significant increment in the levels of antioxidant enzymes on CGM supplementation. The up-regulated gene level expressions of inflammatory markers were down regulated by supplementation of CGM. Supplementation of CGM to arthritic rats significantly improved the histological findings in paw as evident by reduced the massive influx of polymorphonuclear cells infiltration and also CGM protects against excess soft tissue volume, degenerative joint changes, sub-chondral erosion and joint space narrowing by radiological analysis. This current study shows that novel bio-available formulation of curcumin as CGM has an antioxidant, anti-inflammatory and anti-arthritic activity in experimental arthritic model.